Search

You searched for "stone"

1176 results found

The value of Urolink: an OOPE experience

1 May 2019 | | URO - Core Urology
I was fortunate enough to be able to take some time out of my training after ST5 to pursue an Out Of Programme Experience (OOPE) year. During the Urolink meeting at the British Association of Urological Surgeons (BAUS) 2017 conference...

Urology: a missed opportunity for medical students

1 September 2014 | | URO - Core Urology
For those of us lucky enough to have medical students attached to our teams at some time during their undergraduate training, the opportunity undoubtedly represents a refreshing chance to teach well-educated and enthusiastic clinicians at the very start of their...

Uroscopy

1 September 2017 | URO - Technology
In this series of articles I am going to show you some of the exhibits contained in the Museum of Urology, hosted on the BAUS website (www.baus.org.uk). You may feel somewhat distanced from the medical practitioners of mediaeval Florence but...

Unlocking the potential of AI chatbots

4 March 2024 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Infection, URO - Functional / Reconstructive Urology, URO - Neurourology, URO - Paediatric Urology, URO - Technology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology
The landscape of artificial intelligence (AI) is evolving rapidly, and one of its most exciting domains is large language models (LLMs) powering AI chatbots. These models hold immense potential to transform how we interact with technology, offering personalised assistance in...

Sarcomatoid renal cell carcinoma

1 September 2017 | | URO - Urologic Oncology
Renal cell carcinoma (RCC) represents 2-3% of all cancers [1]. It is an adenocarcinoma making up 85% of all renal malignancies. Sarcomatoid transformation is a microscopically identified feature of RCC accounting for 5% of all RCCs [2]. Known as sarcomatoid...

RSM Paediatric Urology Meeting and Presidential Address 2023

4 March 2024 | | URO - Paediatric Urology
The academic year of the Urological Section of the Royal Society of Medicine (RSM) started with a bang in October last year with the Paediatric Urology meeting, co-organised by Shabnam Undre (Paediatric Representative for BAUS and Consultant Paediatric Urologist East...

Clear cell urothelial carcinoma: a highly aggressive morphological variant in the bladder and upper urinary tract

2 November 2023 | | URO - Urologic Oncology
Clear cell urothelial carcinoma (CCUC) is a rare morphological variant of transitional cell carcinoma (TCC). It can occur anywhere along the urothelial tract and is characterised histologically by high grade carcinoma with an abundance of clear, glycogen-rich cytoplasm [1]. Alternative...

Focal therapies in prostate cancer

1 November 2018 | | URO - Urologic Oncology, URO - Technology
The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Rishi Sunak joins Prostate Cancer Research as an ambassador

26 February 2025 | Charities, Research & Development
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...

In conversation with Ahmed Ali

12 May 2025 | URO - Core Urology
We were delighted to chat to Ahmed Ali about the journey to pursing a urological career in the UK and his decision to found the Arabic-British Urological Society. You grew up in Iraq and went to university in Baghdad; what...

Urological Complications of Malignancy

1 January 2014 | | URO - Urologic Oncology
Case 1 1. What does this sagittal magnetic resonance imaging (MRI) scan show? 2. Which cancers commonly cause this? 3. What is the acute management? Case 2 1. What is the diagnosis? 2. What local effects can this mass cause?...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...